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Abstract Human breast cancer cells with a CD44?/
CD24-/low or ALDH1? phenotype have been demon-
strated to be enriched for cancer stem cells (CSCs) using
in vitro and in vivo techniques. The aim of this study was
to determine the association between CD44?/CD24-/low
and ALDH1 expression with clinical–pathologic tumor
characteristics, tumor molecular subtype, and survival in a
well characterized collection of familial breast cancer
cases. 364 familial breast cancers from the Ontario
Familial Breast Cancer Registry (58 BRCA1-associated, 64
BRCA2-associated, and 242 familial non-BRCA1/2 can-
cers) were studied. Each tumor had a centralized pathology
review performed. TMA sections of all tumors were ana-
lyzed for the expression of ER, PR, HER2, CK5, CK14,
EGFR, CD44, CD24, and ALDH1. The Chi square test or
Fisher’s exact test was used to analyze the marker associ-
ations with clinical–pathologic tumor variables, molecular
subtype and genetic subtype. Analyses of the association of
overall survival (OS) with marker status were conducted
using Kaplan–Meier plots and log-rank tests. The CD44?/
CD24-/low and ALDH1? phenotypes were identified in
16% and 15% of the familial breast cancer cases, respec-
tively, and associated with high-tumor grade, a high-
mitotic count, and component features of the medullary
type of breast cancer. CD44?/CD24-/low and ALDH1
expression in this series were further associated with the
basal-like molecular subtype and the CD44?/CD24-/low
phenotype was independently associated with BRCA1
mutational status. The currently accepted breast CSCs
markers are present in a minority of familial breast cancers.
Whereas the presence of these markers is correlated with
several poor prognostic features and the basal-like subtype
of breast cancer, they do not predict OS.
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Introduction
Breast cancer is a highly heterogenous disease at the mor-
phologic and molecular level, with at least four main
molecular subtypes described, including luminal (divided
into luminal A and B), HER2 over-expressing, and basal-
like [1–3]. More recently additional molecular subtypes
have been indentified including claudin-low and molecular
apocrine [4–6]. Each of these subtypes has characteristic
morphologic, immunophenotypic, and prognostic features.
BRCA1-associated breast cancers have been shown to be
enriched with tumors of the basal-like subtype, whereas
BRCA2-associated tumors and familial non-BRCA1-2
tumors are more likely to be of the luminal subtypes [7–11].
The normal epithelium of the breast has been demon-
strated to be organized in a cellular hierarchy with an ER-
negative (-) stem cell giving rise to ER-positive (?) and
ER-negative progenitors, which ultimately give rise to fully
differentiated functional luminal and myoepithelial/basal
epithelium [12, 13]. It has been suggested that the different
molecular subtypes of breast cancer arise from the trans-
formation of different stem or progenitor cell populations
which retain, or acquire as a consequence of the transfor-
mation process some or all of functional characteristics of
normal stem cells [14]. These characteristics include lim-
itless self-renewal capabilities, which drives tumorigenesis,
and the ability to differentiate (albeit aberrantly) leading to
morphologic tumor heterogeneity. There is also evidence to
suggest that it is the CSC population that mediates
metastases and can evade the effects of chemotherapy and
radiation therapy thus promoting recurrence and relapse
[15–22].
A number of markers have been proposed that enrich for
the identification of breast CSCs including CD44 in com-
bination with low or absent expression of CD24 (known as
the CD44?/CD24-/low phenotype) [23, 24] and Aldehyde
dehydrogenase 1 (ALDH1) [25]. CD44 and CD24 are both
adhesion molecules that play major roles in cell–cell and
cell–extracellular matrix (ECM) interactions. CD44 is a
Class I transmembrane glycoprotein that serves as the
primary receptor for hyaluronan [26] and binds other ECM
components, such as collagen, laminin, and fibronectin.
CD44 exists in different splicing variants; some of these
variants have been reported to promote growth, survival,
invasion, and metastatic properties in breast cancer cells
[27–30]. However, other studies on the role of CD44 in
breast cancer have shown opposite effects, suggesting that
CD44’s function in breast cancer is context-dependent
(reviewed [31]). CD24 is a small cell-surface glycoprotein
that binds P-selectin, an adhesion receptor on platelets and
endothelial cells [32]. In addition, CD24 promotes binding
to fibronectin, collagen, and laminin and in agreement with
these functions has been shown to promote adhesion,
migration, and metastasis, and to associate with markers of
poor prognosis in breast cancer [32–34]. ALDH1 is a
detoxifying enzyme responsible for the oxidation of intra-
cellular aldehydes [35] that plays a role in early differen-
tiation of stem cells by promoting the formation of retinoic
acid [36]. In addition to preferential expression of ALDH1
in breast cancer cells with tumor initiating properties [25],
retinoid signaling has been directly implicated in modu-
lating breast cancer stem cell (CSC) differentiation [37].
In the present study, we examine the expression of the
proposed breast CSC markers in a well-characterized col-
lection of familial breast cancer cases. In addition, we
investigated whether the expression of these markers is
associated with any known clinical–pathologic tumor
variables, molecular subtype or with patient survival.
Materials and methods
Study population
The study population included 58 BRCA1-associated, 64
BRCA2-associated, and 242 familial non-BRCA1/BRCA2
tumors from the Ontario Familial Breast Cancer Registry.
All familial non-BRCA1/BRCA2 breast cancers were
obtained from probands within the Breast Cancer Family
Registry who met any of the following criteria for being at
possible genetic risk of breast cancer; at least 1 first-degree
relative with breast or ovarian cancer, at least 2 second-
degree relatives with breast or ovarian cancer, diagnosis
before age 26, male, multiple primaries or breast and
ovarian cancer, at least 1 second-degree or third-degree
relative with male breast cancer, multiple breast, or breast
and ovarian primaries, or breast cancer before 26 years of
age, or ovarian cancer before 60 years of age, Ashkenazi
Jewish, or 3 first degree relatives in the family with breast,
ovarian, colon, prostate or pancreatic cancer or sarcoma
(with one diagnosed before age 50) but who tested negative
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for germline BRCA1 or BRCA2 mutations. Sporadic breast
cancer cases from the registry were not available on TMAs.
Mutational analysis of BRCA1 and BRCA2
Testing for germline mutations in BRCA1 and BRCA2 was
performed using an RNA/DNA-based protein truncation
test with complementary 50 sequencing, as previously
described [38, 39], or by complete gene sequencing by
Myriad Genetics. All mutations were confirmed by DNA
sequencing. Mutations were classified as deleterious if they
were protein-truncating, missense mutations (rare), or
splice-site mutations as defined by the Breast Informatics
Consortium (http://research.nhgri.nih.gov/bic/).
Pathology review
All tumors from the familial breast cancer cohort had a
centralized pathology review performed by an expert breast
pathologist using a standardized checklist form. The
reviewing pathologist was unaware of the mutational status
of the tumor at the time of review. Tumors were classified
according to the WHO histologic classification of breast
tumors and graded using the Nottingham histologic grading
system [40, 41].
TMA construction
A suitable paraffin-embedded block of invasive tumor was
chosen at the time of pathology review and the area of
invasive tumor encircled for TMA construction. Two
0.6 mm cores of tissue were taken from the paraffin tumor
block and used for TMA construction (Beecher Instru-
ments, Sun Praire, WI) as previously described [7, 8]. Four
lm sections were cut and immunohistochemical staining
for ER, PR, HER2, CK5, CK14, EGFR, ALDH1, CD44,
and CD24 was performed using methods as listed in
Table 1. Microwave antigen retrieval was carried out in a
Micromed T/T Mega Microwave Processing Lab Station
(ESBE Scientific, Markham, Ontario, Canada). Sections
were developed with diaminobenzidine tetrahydrochloride
(DAB) and counterstained in Mayer’s hematoxylin.
Interpretation and scoring of immunohistochemistry
Each of the immunohistochemical TMA-stained sections
was scored using Allred’s scoring method [42], which adds
scores for the intensity of staining (absent: 0, weak: 1,
moderate: 2, and strong: 3 to the percentage of cells stained
(none: 0, \1%: 1, 1–10%: 2, 11–33%: 3, 34–66%: 4, and
67–100%: 5 to yield a ‘‘raw’’ score of 0 or 2–8. Previously
validated cut-offs for ER and PR were used (0, 2 = neg-
ative, 3–8 = positive) [43, 44]. Strong complete membra-
nous staining was assessed for HER2 and the cut-off of[5
was used to indicate positivity [45]. For CK5, CK14,
EGFR, CD44, and CD24 a score of C4 was considered
positive, for ALDH1 a score of C5 was considered posi-
tive. The raw score data were reformatted using a TMA
deconvoluter software program into a format suitable for
statistical analysis [46]. The highest score from each TMA
tumor pair was entered into the statistical analysis. Only
the epithelial component of each TMA spot was scored for
the markers indicated. Immunohistochemical results were
recorded as unavailable when the tissue sections were
washed off the slide, TMA cores contained no invasive
tumor cells or when sections were uninterpretable due to
tissue artifact.
Tumors were classified as luminal if they expressed ER
or PR and were negative for HER2. Any tumor with a score
of [5 for HER2, irrespective of the ER status was con-
sidered a HER2 over-expressing tumor and basal-like
tumors were defined as ER, PR, and HER2 negative (triple
negative) and positive for CK5 and/or CK14 and/or EGFR
as previously described [7, 8, 47].
Table 1 Summary of antibodies and their conditions of use
Antibody against Clone Source Dilution Pretreatment
ER 6F11 Vector 1/100 Microwave at 115 C for 12 min in modified Tris–HCl buffer (pH 9)
PR PgR1294 Dako 1/2000 Microwave at 115 C for 12 min in modified Tris–HCl buffer (pH 9)
HER2 A0485 Dako 1/600 Microwave at 115 C for 12 min in modified citrate buffer (pH 6)
CK5 XM26 Vector 1/400 Microwave at 115 C for 12 min in modified Tris–HCl buffer (pH 9)
CK14 LL002 Vector 1/40 Microwave at 115 C for 12 min in modified citrate buffer (pH 6)
EGFR 31G7 Invitrogen 1/35 Microwave at 115 C for 12 min in modified citrate buffer (pH 6)
Ki67 MIB1 Dako 1/300 Microwave at 115 C for 12 min in modified citrate buffer (pH 6)
ALDH1 44ALDH (ALDH1A1) BD Biosciences 1/200 Microwave at 115 C for 12 min in modified Tris–HCl buffer (pH 9)
CD44 DF1485 Dako 1/250 Microwave at 115 C for 12 min in modified citrate buffer (pH 6)
CD24 SN3b Neomarkers 1/45 Microwave at 115 C for 12 min in modified citrate buffer (pH 6)
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Statistical analysis
The Chi square test or Fisher’s exact test was used to
analyze the marker associations with clinical–pathologic
tumor variables, molecular subtype and genetic subtype.
Analyses of the association of OS (overall survival) with
marker status were conducted using Kaplan–Meier plots
and log-rank tests. The follow up data were to the end of
November 24, 2011. Excluding the patients lost to follow-
up and those with deaths, the minimum follow-up time was
12 months after surgery and the median follow-up time
was 148 months. Patient status on November 24, 2011,
determined OS time and censoring status. All tests were
two-sided. A test with a P-value \ 0.05 was considered
statistically significant. P-values were not adjusted for
multiple testing. Statistical analysis of associations was
performed using SAS 9.1 software (SAS Institute, Inc.).




Two hundred and sixty two (262) cases had results for
both CD44 and CD24, of which 41 (16%) had a CD44?/
CD24-/low phenotype (Table 2; Fig. 1a–d). When com-
pared with all other combinations of CD44 and CD24
expression, the CD44?/CD24-/low phenotype was posi-
tively associated with high-tumor grade (p = 0.03), a high-
mitotic score (p = 0.003), margin circumscription
(p = 0.0009), a moderate tumor lymphocytic infiltrate
(p = 0.01), and absent lympho-vascular space invasion
(p = 0.008). In addition there was a statistically non-sig-
nificant trend in association between the CD44?/CD24-/low
phenotype and the lack of lymph-node metastases
(p = 0.09), syncytial tumor growth pattern (p = 0.06) and
young age at diagnosis (p = 0.06). No association was
detected between the CD44?/CD24-/low phenotype and
tumor size, or tumor type.
In the 41 CD44?/CD24-/low cases a molecular pheno-
type was assignable for 33 tumors (Table 3), 16 (48.5%) of
which were basal, 1 (3%) was HER2 overexpressing and
16 (48.5%) were luminal. In comparison to all other
combinations of CD44 and CD24 expression, tumors with
a CD44?/CD24-/low phenotype were more likely to belong
to the basal-like molecular subtype (48.5 vs. 22.2%;
p = 0.0034).
Of the 41 CD44?/CD24-/low cases, 11 (27%) were
BRCA1-associated tumors, 7 (17%) were BRCA2-associ-
ated tumors, and the remainder 23 (56%) were from non-
BRCA1/BRCA2 tumors (Table 4). When compared to all
other combinations of CD44 and CD24 expression, a
CD44?/CD24-/low phenotype was more likely to be asso-
ciated with tumors arising in BRCA1 germline mutation






of CD44 and CD24
(n = 221)
p value
n % n %
Grade
III 31 75.6 118 53.6 0.03
II 6 14.6 73 33.2
I 4 9.8 29 13.2
Size (mm)
0–20 24 58.5 124 56.6 0.97
20–50 15 36.6 83 37.9
[50 2 4.9 12 5.5
Type
Invasive ductal 40 97.6 204 92.7 0.22
Invasive lobular 1 2.4 13 5.9
Other 0 0.0 3 1.4
Lympho-vascular space invasion
Positive 9 22.5 99 45.0 0.008
Negative 31 77.5 121 55.0
Mitotic score
1 9 22.0 82 37.3 0.003
2 3 7.3 46 20.9
3 29 70.7 92 41.8
Number of LN positive
0 26 68.4 109 52.9 0.09
1–3 11 29.0 59 28.6
4–9 1 2.6 30 14.6
C10 0 0.0 8 3.9
Margin circumscription
Positive 19 47.5 49 22.4 0.0009
Negative 21 52.5 170 77.6
Syncytial growth
Positive 7 17.5 16 73 0.06
Negative 33 82.5 203 92.7
Age at diagnosis (years)
\40 21 51.2 72 32.6 0.06
40–50 12 29.3 103 46.6
[50 8 19.5 46 20.8
Lymphocytic infiltrate
Absent (0) 3 7.5 68 31.1 0.01
Weak (1) 6 15.0 17 7.8
Mild (4) 19 47.5 91 41.5
Moderate (5) 12 30.0 43 19.6
LN lymph node
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carriers than non-BRCA1 mutation carriers (26.8 vs.
12.7%; p = 0.02). However, when the analysis was
restricted to basal tumors only (Table 5), there was no
statistical difference in the incidence of CD44?/CD24-/low
expression in BRCA1-associated basal tumors and non-
BRCA1-associated basal tumors.
ALDH1
ALDH1 was expressed in 39 of 255 (15%) tumors
(Table 6; Fig. 2a, b). The expression of ALDH1 was pos-
itively associated with high-tumor grade (p = 0.003), large
tumor size (p = 0.009), high-mitotic score (p = 0.05), a
syncytial growth pattern (p \ 0.0001), a moderate tumor
lymphocytic infiltrate (p = 0.002) and younger age at
diagnosis (p = 0.02). No statistically significant associa-
tion was detected between ALDH1 expression and tumor
type, lympho-vascular space invasion, or lymph-node
status.
A molecular subtype was assignable in 33 of 39 ALDH1
positive tumors, 16 (48.5%) of which were basal, 3 (9%)
were HER2 overexpressing and 14 (42.5%) were luminal
(Table 7). When compared to tumors lacking ALDH1
expression, ALDH1 positive tumors were more commonly
basal-like (48.5 vs. 22.3%; p = 0.007).
Of the 39 ALDH1 expressing tumors, 9 (23%) were
from BRCA1 germline mutation carriers, 9 (23%) were
from BRCA2 germline mutation carriers, and 21 (54%)
were from non-BRCA1/BRCA2 patients (Table 8). There
was no statistically significant association between ALDH1
expression and BRCA1 mutational status (23.1 vs. 14.3%;
p = 0.17), even when the analysis was restricted to
BRCA1 basal-like tumors only (data not shown).
CD44?/CD24-/low/ALDH1?
For the familial breast cancer series the combined CD44?/
CD24-/low/ALDH1? phenotype was expressed in 6 of 230
tumors (data not shown) and associated with a high-mitotic
score (p = 0.04), high-mitotic count (p = 0.03), and a
syncytial growth pattern (p = 0.01). There was a non-
statistically significant trend toward an association with
tumor size (p = 0.09), lympho-vascular space invasion
(p = 0.08), young age at diagnosis (p = 0.08), and tumor
Fig. 1 a BRCA1-associated breast cancer TMA section exhibiting strong membranous staining for CD44 in the majority of invasive tumor cells.
b BRCA1-associated breast cancer TMA section negative for CD24 staining
Table 3 Association between the CD44?/CD24-/low phenotype and
tumor molecular subtype
CD44/CD24 status Molecular subtype p value
Basal HER-2 Luminal
n % n % n %
CD44?/CD24-/low 16 48.5 1 3.0 16 48.5 0.0034
Other combinations of
CD44 and CD24
44 22.2 28 14.1 126 63.7
Table 4 Association between the CD44?/CD24-/low phenotype and
tumor genetic subgroup
CD44/CD24 status Tumor subgroup p value
BRCA1 BRCA2 Familial non-
BRCA1/2
n % n % n %
CD44?/CD24-/low 11 26.8 7 17.1 23 56.1 0.0644
Other 28 12.7 47 21.3 146 66.0
Table 5 Association between the CD44?/CD24-/low phenotype and
tumor genetic subgroup within the basal-like molecular subtype






n % n %
CD44?/CD24-/low 6 37.5 10 62.5 0.69
Other combinations of CD44
and CD24
19 43.2 25 56.8
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lymphocytic infiltrate (p = 0.08). No association was
found between the expression of these combined markers
and tumor grade (p = 0.21), tumor type (p = 1.0), lymph-
node involvement (p = 0.42) or margin circumscription
(p = 0.36).
Only 6 cases expressed a combined CD44?/CD24-/low/
ALDH1? phenotype and while this number of tumors is
too few to perform a robust analysis we did observe that 2
(33%) were basal-like tumors and the remaining 4 (67%)
were luminal tumors. In these 6 tumors, 3 (50%) were from
BRCA1 germline mutation carriers, none (0%) were from
BRCA2 germline mutation carriers and the remaining 3
(50%) were from non-BRCA1/BRCA2 mutation carriers.
When compared to all other combinations of CD44, CD24,
and ALDH1 expression, tumors with a CD44?/CD24-/low/
ALDH1? phenotype were more likely to be associated
with BRCA1 germline mutation carriers than non-mutation
carriers (data not shown). On analysis of the tumors with a
basal-like molecular subtype only (data not shown), there
was no significant difference in CD44?/CD24-/low/
ALDH1? expression between those tumors with and
without a BRCA1 germline mutation.
Survival
There was a non-significant trend toward better survival for
the group with CD44?/CD24-/low compared to the group
with other combinations of CD44 and CD24 (Fig. 3). There
was no difference in survival between patients with tumors
positive for ALDH1 and tumors negative for this marker
(Fig. 4).
Discussion
There is an increasing evidence that many tumors including
breast cancers may be driven by a subpopulation of cells that
display stem cell properties, so called CSCs or tumor initi-
ating cells. Markers have been identified that when used
alone or in combination enrich for functional CSCs, as
defined by their ability to selectively initiate tumors in
immunocompromised mice upon serial passage, a demon-
stration of self renewal, together with the ability to form
tumors that are heterogeneous at the cellular level similar to
the originating tumor, illustrative of the CSC’s ability to
differentiate [48]. These markers include CD44?/CD24-/low
and ALDH1, originally identified by the sorting of cells from
fresh tumors or effusions using flow cytometry or an enzy-
matic assay [23, 25]. Unfortunately fresh tumor samples are
not routinely available for all breast cancer patients and
tumor effusions manifest at a relatively late stage of the
disease process and may not be representative of the primary
tumor. In order to investigate whether CSCs could represent
either prognostic or predictive biomarkers an alterative
approach to their identification must be sought, preferably in
formalin fixed paraffin embedded (FFPE) tumor material
which represents the bulk of patient tumor samples
and clinical trial archives. In this study we have







n % n %
Grade
III 30 79.0 112 52.1 0.0033
II 8 21.0 69 32.1
I 0 0.0 34 15.8
Size (mm)
0–20 14 36.9 133 62.2 0.0099
20–50 20 52.6 72 33.6
[50 4 10.5 9 4.2
Type
Invasive ductal 36 94.8 198 92.1 1.0000
Invasive lobular 1 2.6 11 5.1
Other 1 2.6 6 2.8
Lympho-vascular space invasion
Positive 16 42.1 87 40.7 0.8668
Negative 22 57.9 127 59.3
Mitotic score
1 8 21.0 85 39.5 0.0549
2 6 15.8 37 17.2
3 24 63.2 93 43.3
Number of LN positive
0 20 57.1 118 59.0 0.7104
1–3 8 22.9 53 26.5
4–9 6 17.1 21 10.5
C10 1 2.9 8 4.0
Margin circumscription
Positive 15 39.5 53 24.9 0.0623
Negative 23 60.5 160 75.1
Syncytial growth
Positive 10 26.3 13 6.1 \0.0001
Negative 28 73.7 200 93.9
Age at diagnosis (years)
\40 21 53.9 69 32.0 0.0214
40–50 10 25.6 99 45.8
[50 8 20.5 48 22.2
Lymphocytic infiltrate
Absent 4 10.5 64 30.0 0.0025
Weak 7 18.4 16 7.5
Mild 13 34.2 93 43.7
Moderate 14 36.9 40 18.8
LN lymph node
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used immunohistochemical (IHC) expression of CD44?/
CD24-/low and ALDH1 as surrogate markers for breast CSCs
and sought to correlate their expression alone and in com-
bination with clinical–pathologic tumor features, breast
cancer molecular subtypes, germline gene mutations, and
ultimately patient outcome.
Our observations suggest that only a minority of the
tumors examined contained cells expressing the breast
CSC phenotypes CD44?/CD24-/low(15%), ALDH1 (16%)
or both combined CD44?/CD24-/low/ALDH1? (\1%).
Other investigators employing IHC methods to identify
these phenotypes have reported a wide variance in the
percentage of primary breast tumors that express these
phenotypes: 20–60% of tumors exhibit some cells with a
CD44?/CD24-/low phenotype [49–55], whereas 7–70% of
tumors examined expressed ALDH1 [22, 25, 52, 54, 56–
61]. These differences may reflect differences in the anti-
bodies employed, or the tumor populations examined e.g.,
familial vs sporadic, or the scoring cut points applied (for
example, some studies considered tumors with as few as
one cell positive for the markers to be positive [50, 59]
whereas others like this study have required a minimum of
10% of tumor cells to express the marker in question for
the tumor to be considered positive [52, 54]). Alternatively,
Fig. 2 a Tumor section exhibiting moderate cytoplasmic positivity for ALDH1 in approximately 50% of tumor cells. b Tumor section negative
for ALDH1 staining, the macrophages in the tumor stroma demonstrate strong cytoplasmic staining for ALDH1
Table 7 Association between ALDH1 expression and tumor
molecular subtype
ALDH1 status Molecular subtype p value
Basal HER-2 Luminal
n % n % n %
Positive 16 48.5 3 9.1 14 42.4 0.007
Negative 43 22.3 24 12.4 126 65.3
Table 8 Association between ALDH1 expression and tumor genetic
subgroup
ALDH1 status Tumor subgroup p value
BRCA1 BRCA2 Control
n % n % n %
Positive 9 23.1 9 23.1 21 53.8 0.2869
Negative 31 14.4 43 19.9 142 65.7



































Fig. 3 Kaplan–Meyer plots demonstrating survival groups according
to CD44/CD24 expression



































Fig. 4 Kaplan–Meyer plots demonstrating survival groups according
to ALDH1 expression
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perhaps CSCs are phenotypically more diverse and the two
phenotypes we have examined may not capture all possible
breast CSCs. Wright et al. [62] in an examination of CSCs
from transgenic mice engineered to be deficient in BRCA1
demonstrated that some tumors contained CSCs with a
CD44?/CD24-/low phenotype, whereas other tumors con-
tained CSC characterized by CD133 expression. Other
markers identified as putative breast CSC markers include
CK5, EGFR, EpCAM, and CD49f [63, 64].
Traditionally in breast cancer a number of clinical–
pathologic tumor characteristics are associated with poor
prognosis and include; younger age at diagnosis, large tumor
size, lymph-node involvement, high-tumor grade, lympho-
vascular space invasion (LVSI), negative hormonal receptor
status, and HER2 over-expression [65, 66]. Patients with
tumors displaying some or all of these features are consid-
ered at increased risk for relapse and death from breast
cancer when compared to patients with tumors lacking these
features. In this study, we demonstrated a positive associa-
tion between the presence of cells with a CSC phenotype
(CD44?/CD24-/low or ALDH1 positive or both) and many
of these adverse prognostic features including high-tumor
grade, large tumor size, and younger age at diagnosis. A
number of other studies have reported similar associations
between the presence of CSCs and adverse prognostic fea-
tures [49, 52, 53]. Interestingly, despite the association with
some adverse prognostic factors we were unable to dem-
onstrate an association between CD44?/CD24-/low or
ALDH1 expression and breast cancer outcome. We are not
alone in this observation, in 2 of 4 other studies where the
expression of CD44?/CD24-/low was analyzed in relation to
outcome no association was observed [51, 54], in the third
study an association between CD44?/CD24-/low and out-
come was significant on univariate analyses only [53],
whereas in the fourth an inverse relationship between
CD44?/CD24-/low expression and survival was reported
[55]. The expression of ALDH1 has been correlated with
poor patient prognosis in some but not all studies [25, 54, 57,
58, 61, 67]. In two studies the expression of ALDH1 was
found to be an independent prognostic variable after mul-
tivariate analyses [25, 57]. However, similar to our study
Ricardo et al. [54] and Resetkova et al. [61] failed to dem-
onstrate an association between ALDH1 expression and
outcome. The lack of an association between these markers
and patient survival in a number of studies may suggest that
the presence of cells with a stem cell phenotype is not a
prognostic marker or alternatively that the identification of
these markers by immunohistochemistry may not accurately
identify the functional CSC population within a tumor.
In our study, the CD44?/CD24-/low and ALDH1 phe-
notypes were positively associated with the component
features of medullary-type breast cancer; namely promi-
nent lymphocytic infiltrate, pushing tumor margins and
syncytial growth pattern [68]. Medullary cancer is a special
subtype of breast cancer that occurs in 1–5% of all cases,
these cancers are ER, PR, and HER2 negative and char-
acteristically high grade [40, 69]. Furthermore, they have
been demonstrated to cluster with either basal-like or
claudin-low molecular subtypes of breast cancer and to be
more commonly represented in tumors of BRCA1 mutation
carriers [3, 5, 70, 71]. Despite these seemingly adverse
morphologic and molecular associations medullary-type
cancers are associated with a better prognosis than non-
medullary grade III tumors a fact that may result from the
prominent host lymphocytic response that characterizes
these tumors [69]. A prominent tumor lymphocytic infil-
trate has been demonstrated to be a good prognostic factor
in ER-negative breast cancer and basal-like breast cancers
specifically [72–74]. It is plausible that the presence of an
‘‘anti-tumor’’ immune response in the tumor stroma may
mitigate the effects of the increase in CSCs present in these
tumor types.
The basal-like subtype of breast cancer is a molecular
subtype that was originally discovered through gene
expression profiling studies [1–3, 75]. This subtype if
predominantly triple negative (ER, PR, and HER2 nega-
tive) and associated, at least in the short-term, with a worse
prognosis than ER-positive luminal-type tumors [76–78].
Breast tumors from patients with BRCA1 germline muta-
tions are enriched for this subtype [3, 7, 9]. In this study,
we demonstrate that both CSCs expressing either the
CD44?/CD24-/low or ALDH1 positive phenotype are more
commonly found in basal-like tumors than any other
molecular subtype examined. Furthermore, we demon-
strated a positive association between BRCA1 mutational
status and the CD44?/CD24-/low phenotype. BRCA1 is
believed to be a regulator of breast stem cell fate and is
required for mammary epithelial cell differentiation [79,
80]. Specifically, BRCA1 is required for the differentiation
of ER- luminal progenitor cells and in its absence, such as
in the epithelium of BRCA1 mutation carriers, the trans-
formed luminal progenitors are ‘‘driven’’ toward a basal
cell fate (expressing CK5), hence the predominance of the
basal-like tumor phenotype among BRCA1 mutation car-
riers [64, 81, 82]. Sporadic basal-like breast cancer arising
in patients without germline BRCA1 mutations are often
deficient in functional BRCA1 protein resulting in a similar
pathway for the development of sporadic and BRCA1-
associated basal-like breast cancer and hence a similar
phenotype and CSC expression [83]. Honeth et al. [50]
profiled 17 BRCA1-associated breast cancers for the
CD44?/CD24-/low phenotype and found that 94% of their
BRCA1-associated tumors expressed this phenotype as did
63% of the sporadic basal-like breast cancer included in
the study. Heerma van Voss et al. [56] demonstrated
that ALDH1 was an independent predictor of BRCA1
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mutational status, whereas in our larger cohort of BRCA1-
associated tumors ALDH1 was not associated with BRCA1
status but rather with the basal-like subtype only.
In our study, a very small fraction of tumors examined
(6 of 230 tumors or 0.03%) expressed both CSC pheno-
types. Unfortunately, this small number of cases precludes
robust statistical analysis but another study by Rimm et al
using AQUA technology on the Yale breast cancer cohort
showed that 5.5% of breast tumors examined contained
cells that co-expressed both CD44 and ALDH1 and these
tumors were associated with a high breast cancer-specific
mortality [67]. This is in agreement with observations by
Ginestier et al. [25], who have shown that tumor cells
expressing both phenotypes are highly tumorigenic with
the capacity to generate tumors from as few as 20 cells
in vivo.
In conclusion, we have demonstrated that CSCs as
defined by the expression of CD44?/CD24-/low and/or
ALDH1 are present in a minority of familial breast cancer
cases. The expression of these CSC phenotypes is associ-
ated with a number of adverse prognostic clinical–patho-
logic features but not with overall survival. In addition, we
have demonstrated that the expression of CD44?/CD24-/
low and/or ALDH1 is more common in basal-like tumors
and that there is an association between BRCA1 mutational
status and CD44?/CD24-/low expression.
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